Explore how patients with oHCM may underrecognize symptoms despite treatment. Learn the role of targeted questioning, identify persistent functional limitations, and understand evolving disease-focused management approaches.
6 questions
Which factor most commonly leads patients with obstructive hypertrophic cardiomyopathy (oHCM) on standard-of-care therapy to underreport persistent symptoms to healthcare professionals (HCPs)?
Correct Answer: B
In oHCM, functional limitations often develop gradually. Patients may adapt their activity levels over time and accept reduced capacity as their new baseline, leading to underrecognition and underreporting of symptoms.
https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1387596/full
https://pmc.ncbi.nlm.nih.gov/articles/PMC12374203/pdf/main.pdf
https://link.springer.com/article/10.1007/s40265-022-01728-w
https://www.sciencedirect.com/science/article/pii/S0735109724080938
https://pmc.ncbi.nlm.nih.gov/articles/PMC11396639/pdf/jcm-13-05239.pdf
https://www.jacc.org/doi/epdf/10.1016/j.jacc.2024.09.003
What is the primary benefit of targeted clinical questioning in patients with oHCM who appear “stable” on standard-of-care therapy?
Correct Answer: D
Patients with oHCM may experience limitations in daily activities that are not spontaneously reported. Targeted questioning can help uncover functional impairment and symptom burden that might otherwise remain unrecognized.
What is a key limitation of conventional first-line therapies for oHCM?
Correct Answer: C
Conventional therapies improve symptoms by reducing heart rate and contractility, thereby lowering left ventricular outflow tract obstruction. However, they may not directly target sarcomere hypercontractility, a key contributor to disease pathophysiology in oHCM.
Cardiac myosin inhibition primarily targets which pathophysiologic mechanism in oHCM?
Cardiac myosin inhibitors modulate actin–myosin interactions and shift myosin toward a more energy-efficient state, reducing sarcomere hypercontractility. This mechanism has been associated with reductions in left ventricular outflow tract obstruction and related symptoms.
Clinical studies of cardiac myosin inhibition in symptomatic oHCM have been associated with which of the following outcomes?
Correct Answer: A
Clinical studies suggest that cardiac myosin inhibition may be associated with reductions in left ventricular outflow tract gradients and improvements in symptoms, exercise capacity, and functional status.
Which approach best reflects the role of HCPs in optimizing care for patients with oHCM receiving standard-of-care therapy?
Patients with oHCM may underrecognize or underreport symptoms. HCPs play a key role in proactively reassessing symptom burden through targeted questioning and considering whether additional or advanced treatment strategies are appropriate, particularly when functional limitations persist despite standard-of-care therapy.